课题基金 / 基金详情

HIV-2--A MODEL OF HIV PRIMARY INFECTION

HIV-2--A MODEL OF HIV PRIMARY INFECTION
HIV-2——HIV原发感染模型
批准号:
6534121
负责人:
Phyllis J. Kanki
金额:
$42.58万
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-09-01 至 2004-08-31

项目摘要

项目成果

Phyllis J. Kanki的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (adapted from the Abstract): Studies of HIV2-infected individuals have demonstrated a significantly slower progression to AIDS. Most HIV-1 cohort studies have found 5-15% of their participants fit a definition of long-term non-progression, whereas 86-95% of HIV-2 infected individuals would be similarly classified. This dramatic difference in pathogenicity provides a unique opportunity to identify viral and host immune mechanisms involved in closely related and relevant virus system that is predicted to have a significantly slower course of progression. Significant advances in our understanding of HIV pathogenesis have come from studies of primary HIV-1 infection. The Principal Investigator proposes to characterize primary HIV-2 infection as a model system for long-term non-progressive HIV infection. The full spectrum of HIV primary infection will be assessed by recruiting women from a sub-selected high risk population, frequently monitored for early virologic and immunologic evidence of infection, irrespective of clinical symptomatology. By characterizing the cellular immune responses and viral characteristics found in primary HIV-2 infection, the Investigator believe that critical early determinants of HIV pathogenicity may be elucidated. She speculates that the lower pathogenicity of HIV-2 will be reflected in distinct difference sin the cellular immune responses to this virus during primary infection. Such responses would likely lower viral replication during this critical period of infection, resulting in a lowered viral set-point predictive of long progression. The identification of temporal, qualitative, and quantitative aspects of these immune responses should contribute to out growing understanding of the determinants of HIV pathogenicity.
期刊论文(8)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1097/01.qhv.0000021465.39141.02
发表时间: 2002-01-01
期刊: JOURNAL OF HUMAN VIROLOGY
影响因子: --
作者: [Diouf, K, Sarr, AD, Kanki, P]
通讯作者: Kanki, P
Molecular epidemiology of human immunodeficiency virus type 1 sub-subtype A3 in Senegal from 1988 to 2001.
1988年至2001年塞内加尔人类免疫缺陷病毒1型A3亚型的分子流行病学。
DOI: 10.1128/jvi.78.22.12455-12461.2004
发表时间: 2004
期刊: Journal of virology
影响因子: 5.4
作者: [Meloni,SeemaThakore, Sankalé,Jean-Louis, Hamel,DonaldJ, Eisen,Geoffrey, Guéye-Ndiaye,Aissatou, Mboup,Souleymane, Kanki,PhyllisJ]
通讯作者: Kanki,PhyllisJ
The absence of anti-Tat antibodies is associated with risk of disease progression in HIV-2 infection.
抗 Tat 抗体的缺乏与 HIV-2 感染疾病进展的风险相关。
DOI: 10.1086/507042
发表时间: 2006
期刊: The Journal of infectious diseases.
影响因子: --
作者: [Rodriguez,ShaunK, Sarr,AbdoulayeDieng, Olorunnipa,Olushola, Popper,StephenJ, Gueye-Ndiaye,Aissatou, Traore,Ibrahima, Dia,MamadouC, Mboup,Souleymane, Kanki,PhyllisJ]
通讯作者: Kanki,PhyllisJ
Viral dynamics of primary HIV-1 infection in Senegal, West Africa.
西非塞内加尔原发性 HIV-1 感染的病毒动态。
DOI: 10.1086/429409
发表时间: 2005
期刊: The Journal of infectious diseases
影响因子: --
作者: [Sarr,AbdoulayeDieng, Eisen,Geoffrey, Guèye-Ndiaye,Aissatou, Mullins,Christopher, Traoré,Ibrahima, Dia,MamadouCiré, Sankalé,Jean-Louis, Faye,Diegane, Mboup,Souleymane, Kanki,Phyllis]
通讯作者: Kanki,Phyllis
Doctoral Training Program in Tropical Diseases
  • 批准号:
    8906721
  • 项目类别:
  • 资助金额:
    $23.18万
  • 财政年份:
    2001
  • 负责人:
    Phyllis J. Kanki
  • 依托单位:
Doctoral Training Program in Tropical Diseases
  • 批准号:
    9069380
  • 项目类别:
  • 资助金额:
    $23.31万
  • 财政年份:
    2001
  • 负责人:
    Phyllis J. Kanki
  • 依托单位:
The Graduate Program in Tropical Infectious Diseases (GPiTID)
  • 批准号:
    9793256
  • 项目类别:
  • 资助金额:
    $17.85万
  • 财政年份:
    2001
  • 负责人:
    Phyllis J. Kanki
  • 依托单位:
The Graduate Program in Tropical Infectious Diseases (GPiTID)
  • 批准号:
    10641789
  • 项目类别:
  • 资助金额:
    $20.78万
  • 财政年份:
    2001
  • 负责人:
    Phyllis J. Kanki
  • 依托单位:
海外基金